{"disease":{"id":"malaria-prophylaxis","name":"malaria prophylaxis"},"drugs":{"marketed":[{"drug_id":"hydroxychloroquine","indication_name":"Malaria prophylaxis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"HYDROXYCHLOROQUINE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":75,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and reducing inflammation in the body."},{"drug_id":"tafenoquine","indication_name":"Malaria Prophylaxis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Krintafel","generic_name":"TAFENOQUINE","company_name":"60 Degrees Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"tafenoquine","quality_score":55,"revenue":null,"mechanism":"Tafenoquine works by targeting the parasite's heme detoxification pathway, preventing the parasite from producing heme and ultimately leading to its death."},{"drug_id":"doxycycline","indication_name":"Malaria prophylaxis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05874869","title":"Dihydroartemisinin-piperaquine for Seasonal Malaria Chemoprophylaxis in Tanzania","phase":"NA","overall_status":"COMPLETED","enrollment_count":13800,"lead_sponsor_name":"Richard Mwaiswelo","has_results":false},{"nct_id":"NCT04816461","title":"Boosting the Impact of SMC Through Simultaneous Screening and Treatment of Roommates","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":526,"lead_sponsor_name":"Institut de Recherche en Sciences de la Sante, Burkina Faso","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}